Publications by authors named "Lourdes Porras"
Introduction: The APLICOV-PC study assessed the safety and preliminary efficacy of plitidepsin in hospitalized adult patients with COVID-19. In this follow-up study (E-APLICOV), the incidence of post-COVID-19 morbidity was evaluated and any long-term complications were characterized.
Methods: Between January 18 and March 16, 2022, 34 of the 45 adult patients who received therapy with plitidepsin in the APLICOV-PC study were enrolled in E-APLICOV (median time from plitidepsin first dose to E-APLICOV enrollment, 16.
Article Synopsis
- - Plitidepsin, a cyclic-peptide from marine sources, effectively inhibits SARS-CoV-2 replication by targeting an important host protein, showing its strongest effects in lung tissue compared to blood.
- - A clinical study involving 46 hospitalized COVID-19 patients tested three doses of plitidepsin and primarily focused on safety, while also monitoring viral load changes, mortality, and need for respiratory support.
- - The treatment was generally safe, with some common side effects like nausea, vomiting, and diarrhea; early results indicated significant reductions in viral load over time, though a few patients required additional medical support.
Unlabelled: Plitidepsin is a marine-derived cyclic-peptide that inhibits SARS-CoV-2 replication at low nanomolar concentrations by the targeting of host protein eEF1A (eukaryotic translation-elongation-factor-1A). We evaluated a model of intervention with plitidepsin in hospitalized COVID-19 adult patients where three doses were assessed (1.5, 2 and 2.
View Article and Find Full Text PDFWe retrospectively investigated the impact of high vancomycin minimum inhibitory concentration (MIC > 2 μg/ml) on the outcome of 53 patients with bacteremia caused by methicillin-susceptible Staphylococcus aureus (MSSA). Vancomycin MIC was determined by broth microdilution according to CLSI methods. The primary outcome was 30-day all-cause mortality from the date of the first positive blood culture.
View Article and Find Full Text PDFBackground: Wegener's granulomatosis (WG) is a complex disease, characterized by a necrotizing vasculitis that usually involves the upper airways, lungs, and kidneys; occasionally, other organs may also be affected. Because of the severity and rapid progression of the disease, early diagnosis and treatment are critical; this type of vasculitis is potentially fatal if left unchecked.
Methods: A 64-year-old woman presented with a chief complaint of a gingival mass that had appeared 2 months before and had grown rapidly.